Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant GEMOX + lenvatinib + tislelizumab and adjuvant capecitabine + tislelizumab for high‑risk resectable biliary tract cancers
ChiCTR2600130831Phase 2Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin, lenvatinib, tislelizumab and capecitabine in intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: Major pathological response. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatinlenvatinibtislelizumabcapecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on ChiCTR2600130831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130831.